- Home
- CLPR vs CTSO Comparison
CLPR vs CTSO Comparison
Compare CLPR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | CTSO |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | 171 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 45.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | CTSO |
|---|---|---|
| Price | $3.50 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 61.0K | ★ 126.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | ★ 10.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,179,000.00 | $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.90 | ★ 23.89 |
| 52 Week Low | $3.37 | $0.60 |
| 52 Week High | $6.49 | $1.61 |
Technical Indicators
Market Signals| Indicator | CLPR | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 47.96 |
| Support Level | $3.37 | $0.70 |
| Resistance Level | $3.65 | $0.75 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.92 | 56.00 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.